Retirement Guys Formula LLC Has $2.64 Million Stock Holdings in Johnson & Johnson $JNJ

Retirement Guys Formula LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 66.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,256 shares of the company’s stock after purchasing an additional 5,708 shares during the period. Johnson & Johnson comprises about 0.9% of Retirement Guys Formula LLC’s holdings, making the stock its 27th largest holding. Retirement Guys Formula LLC’s holdings in Johnson & Johnson were worth $2,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the stock. Clark Asset Management LLC grew its holdings in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina boosted its position in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the period. Avanza Fonder AB boosted its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the period. Talbot Financial LLC grew its holdings in Johnson & Johnson by 4.6% during the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after acquiring an additional 6,143 shares during the last quarter. Finally, Winnow Wealth LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $295,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Argus set a $210.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $207.26 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $201.17 and a two-hundred day simple moving average of $183.07. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The firm has a market capitalization of $499.35 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.